The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth Syndrome
NCT ID: NCT05309070
Last Updated: 2025-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2022-05-01
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
N Acetylcystene in Treatment of Radiotherapy Induced Oral Mucositis in Oral Cancer Patients
NCT07082621
Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers
NCT02868151
Effect of N-acetyl Cysteine and Zinc in Management of Head and Neck Cancer Radiotherapy Induced Oral Mucositis
NCT06482034
Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.
NCT06354712
Oral Glutamine and Mucositis of Head and Neck Cancer Patients Undergoing Radiation
NCT02282839
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose and protocol of the research will be explained to the patients. If they are willing to participate, they will sign an informed consent previously approved by the Ethics Committee of the Faculty of Dentistry. They will fill in the OHIP-14 questionnaire and the VAS scale, grading from 0-10, where 0 indicates a condition without symptoms, and 10 the strongest possible intensity of symptoms. They will be randomly assigned to a therapeutic or placebo group and will receive the medicine in an unmarked box. The drug will be taken for two months at a dose of 1200 mg per day. After that, they will come for a check-up and re-complete OHIP-14 and record the intensity of symptoms according to the VAS scale.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
female patients with primary burning mouth syndrome
N-acetyl cysteine
Study group will receive N-acetyl cysteine in unmarked boxes, in a daily dose of 1200 mg during two months
Control group
female patients with primary burning mouth syndrome
placebo
Control group will receive a placebo, in unmarked boxes, during two months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-acetyl cysteine
Study group will receive N-acetyl cysteine in unmarked boxes, in a daily dose of 1200 mg during two months
placebo
Control group will receive a placebo, in unmarked boxes, during two months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* anamnestic data about active gastric or duodenal ulcer
* decreased levels of serum iron or B vitamins
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zagreb
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Božana Lončar Brzak
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
School of Dental Medicine, University of Zagreb
Zagreb, , Croatia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-PA-30-III-12/2021.
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.